

The drug, Chemet (succimer), is subject to the prior authorization process.

PROCEDURE

Initial Authorization Criteria:

Must meet all of the criteria listed below:

- Must be prescribed by a toxicologist or other clinician who has experience with chelating agents
- Must have diagnosis of lead poisoning with a blood lead level above 45µg/dL
- Must have chart documentation of identification and removal of the cause of lead exposure

Reauthorization Criteria:

All prior authorization renewals are reviewed on a case-by-case basis to determine the Medical Necessity for continuation of therapy. Authorization may be extended on a case-by-case basis based upon the above criteria and clinical rationale from the prescriber for continuation of treatment.

Limitations:

Length of Authorization (if above criteria met)	
Initial Authorization	Up to 1 month
Reauthorization	Same as initial

If the established criteria are not met, the request is referred to a Medical Director for review.

REFERENCES

1. Chemet [prescribing information]. Ovation Pharmaceuticals: Deerfield, IL; July 2007.
2. Shannon MW, Best D, Binns, HJ, et al. Lead exposure in children: prevention, detection, and management. *Pediatrics*. 2005;116:1036-1045.

RECORD RETENTION

Records Retention for Evolent Health documents, regardless of medium, are provided within the Evolent Health records retention policy and as indicated in CORP.028.E Records Retention Policy and Procedure.



Chemet (succimer)
POLICY NUMBER: RX.PA.212.E
REVISION DATE: N/A
PAGE NUMBER: 3 of 3

REVIEW HISTORY

DESCRIPTION OF REVIEW / REVISION	DATE APPROVED
<i>Annual review</i>	02/17, 02/18

